Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.35 |
| ▸ | CSK | P41240 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876249 | 0.84 | ANPEP (0.39) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL4868358 | 0.81 | ANPEP (0.36) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL404157 | 0.79 | MMP1 (0.36) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL4876777 | 0.78 | ANPEP (0.37) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL2157193 | 0.75 | SMN1; SMN2 (0.33) | CYP1A2 | |
| SCHEMBL27805645 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL5650452 | 0.74 | ALDH1A1 (0.42) | CYP3A4 | |
| SCHEMBL27734190 | 0.74 | MMP9 (0.37) | HDAC4MMP8 | |
| SCHEMBL403198 | 0.73 | CHEK1 (0.32) | — | |
| SCHEMBL4878757 | 0.72 | ITGB1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | ANPEP 744/4885CSK 2473/4885CYP1A2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.